A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
The primary objective of this study was to compare progression-free survival in patients
with multiple myeloma who relapsed after 1 to 3 prior therapies treated with carfilzomib
plus dexamethasone or bortezomib plus dexamethasone.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society